MSACL 2018 US Abstract

Topic: Practical Training

Financial Considerations for Purchasing a Mass Spectrometer_III

Joe El-Khoury (Presenter)
Yale University

Bio: Joe El-Khoury is Assistant Professor of Laboratory Medicine at Yale University and the Co-Director of the Clinical Chemistry Laboratory and Clinical Chemistry Fellowship program at Yale-New Haven Health. He is board certified by the American Board of Clinical Chemistry (ABCC) and a fellow of the National Academy for Clinical Biochemistry (NACB). He completed his post-doctoral fellowship training in Clinical Biochemistry at Cleveland Clinic, Cleveland, OH.

Authorship: Joe El-Khoury
Yale University

Short Abstract

Starting mass spectrometry testing in your laboratory, or adding a new mass spectrometer, is a daunting task. How do you make the right decision? And how do you finance this purchase? This session will discuss the financial considerations of purchasing a mass spectrometry system as well as return on investment calculation and negotiation with vendors. Audience participation will be encouraged!

Long Abstract

Introduction

The best way to convince your administrator that you should buy a mass spectrometer is to talk dollars! This session will discuss the monetary and clinical benefits of purchasing a mass spectrometer, financial considerations such as return on investment calculation, how to finance the purchase and negotiation with vendors.

Audience participation will be encouraged!

Methods

Results

Conclusions & Discussion

Learning objectives of this session:

1. Explain the financial components that should be considered when purchasing a mass spectrometer.

2. Calculate the return on investment for the purchase of a mass spectrometer.

3. Describe the options for financing a mass spectrometer and potential points for negotiation.


References & Acknowledgements:


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno

IP Royalty: no

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no